Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation.
|
31577767 |
2019 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Olaparib is a PARP inhibitor (PARPi).For patients bearing BRCA1 or BRCA2 mutations, olaparib is approved to treat ovarian cancer and in clinical trials to treat breast and pancreatic cancers.
|
30660828 |
2019 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We confirmed variants in BRCA2 as the most common high-penetrant genetic factor associated with pancreatic cancer and we also identified candidate pancreatic cancer genes.
|
29074453 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
|
30407790 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
|
29441441 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this study, we determined protein expression of BRCA1 and BRCA2 in 4 digestive system cancers (gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer) by immunohistochemistry on tissue microarrays.
|
29126833 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Since its identification as a BRCA2 interacting partner, PALB2 has emerged as a pivotal tumor suppressor protein associated to hereditary cancer susceptibility to breast and pancreatic cancers.
|
28858227 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient).
|
28767289 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.
|
28452926 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the index patient a germline mutation both in the APC and BRCA2 gene was identified while one affected brother showed the BRCA2 mutation only and another brother is supposed to have developed pancreatic cancer due to multiple non-genetic risk factors.
|
27838800 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Here we present a case of a 63-year-old female patient with a germ line pathogenic BRCA2 mutation (6714 deletion) who developed pancreatic cancer and had an exceptional response to platinum and PARP inhibitor therapy.
|
28291774 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations in MSH2/MLH1-mutant CRCs included 75 unique mutations not known to occur in breast or pancreatic cancer per COSMIC v73.
|
28591715 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The BRCA2 gene is one of the most common genes linked to pancreatic-only cancer families; however, other hereditary cancer syndromes have also been associated with an increased risk for PC.
|
26727920 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Consequently, inherited mutations in BRCA2 are associated with an increased risk of breast, ovarian and pancreatic cancers.
|
27530658 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we asked whether radiation sensitivity of pancreatic cancers developing in individuals with germline BRCA2 mutations can be enhanced by agents that inhibit poly (ADP-ribose) polymerase (PARP).
|
28033382 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Nucleotide sequencing of BRCA2 in lymphocyte and tumoral DNA of a 50-year-old male who presented with an androgen-secreting ACC and a strong family history of breast, ovarian, and pancreatic cancers.
|
27603373 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
|
28078281 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
|
25864590 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found that AZD1775 sensitized to gemcitabine-radiation in BRCA2 wild-type but not BRCA2 mutant pancreatic cancer cells.
|
26585231 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Targeting defects in the DNA repair machinery of neoplastic cells, for example, those due to inactivating BRCA1 and/or BRCA2 mutations, has been used for developing new therapies in certain types of breast, ovarian and pancreatic cancers.
|
26511885 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_human |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
|
24737347 |
2014 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2, and establish valuable new preclinical settings for testing approaches to pancreatic cancer therapy; together, these features emphasize the value of GEMMs in cancer research.
|
24268522 |
2014 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA1 and BRCA2 are associated with an increased risk of pancreatic cancer.
|
23456555 |
2013 |